Cancer Drug Discovered with ALS Help Enters Phase 2 Trials
Seeking to develop a direct inhibitor of a mutant protein caused by errors in the KRAS gene, researchers at Amgen conducted X-ray crystallography of KRAS(G12C) proteins using the Berkeley Center for Structural Biology (BCSB) beamlines at the Advanced Light Source (ALS). The high-resolution structural maps generated from the data acquired revealed a small pocket on the molecule. Now, an investigational cancer drug that binds in this pocket will be evaluated in phase 2 clinical trials.
More »